Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 21788357)

1.

Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells.

von Baumgarten L, Brucker D, Tirniceru A, Kienast Y, Grau S, Burgold S, Herms J, Winkler F.

Clin Cancer Res. 2011 Oct 1;17(19):6192-205. doi: 10.1158/1078-0432.CCR-10-1868. Epub 2011 Jul 25.

2.

Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation.

Vidiri A, Pace A, Fabi A, Maschio M, Latagliata GM, Anelli V, Piludu F, Carapella CM, Giovinazzo G, Marzi S.

J Exp Clin Cancer Res. 2012 Apr 11;31:33. doi: 10.1186/1756-9966-31-33.

3.

Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.

Mathieu V, De Nève N, Le Mercier M, Dewelle J, Gaussin JF, Dehoux M, Kiss R, Lefranc F.

Neoplasia. 2008 Dec;10(12):1383-92.

4.

Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.

Kuroda J, Kuratsu J, Yasunaga M, Koga Y, Kenmotsu H, Sugino T, Matsumura Y.

Clin Cancer Res. 2010 Jan 15;16(2):521-9. doi: 10.1158/1078-0432.CCR-09-2393. Epub 2010 Jan 12.

5.

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.

de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA.

Neuro Oncol. 2010 Mar;12(3):233-42. doi: 10.1093/neuonc/nop027. Epub 2010 Jan 6.

6.

Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.

Saidi A, Hagedorn M, Allain N, Verpelli C, Sala C, Bello L, Bikfalvi A, Javerzat S.

Int J Cancer. 2009 Sep 1;125(5):1054-64. doi: 10.1002/ijc.24380.

PMID:
19431143
7.

High-dose antiangiogenic therapy for glioblastoma: less may be more?

de Groot JF.

Clin Cancer Res. 2011 Oct 1;17(19):6109-11. doi: 10.1158/1078-0432.CCR-11-1853. Epub 2011 Aug 18.

8.

Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.

Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF.

Clin Cancer Res. 2013 Aug 15;19(16):4392-403. doi: 10.1158/1078-0432.CCR-12-1557. Epub 2013 Jun 26.

9.

Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.

Lucio-Eterovic AK, Piao Y, de Groot JF.

Clin Cancer Res. 2009 Jul 15;15(14):4589-99. doi: 10.1158/1078-0432.CCR-09-0575. Epub 2009 Jun 30.

10.

Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.

Zhou F, Hu J, Shao JH, Zou SB, Shen SL, Luo ZQ.

J Cancer Res Clin Oncol. 2012 Nov;138(11):1879-90. doi: 10.1007/s00432-012-1270-7. Epub 2012 Jun 27.

PMID:
22736027
11.

Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.

LaViolette PS, Cohen AD, Prah MA, Rand SD, Connelly J, Malkin MG, Mueller WM, Schmainda KM.

Neuro Oncol. 2013 Apr;15(4):442-50. doi: 10.1093/neuonc/nos323. Epub 2013 Feb 3.

12.

Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: from bedside to bench.

Burkhardt JK, Hofstetter CP, Santillan A, Shin BJ, Foley CP, Ballon DJ, Pierre Gobin Y, Boockvar JA.

J Clin Neurosci. 2012 Nov;19(11):1568-72. doi: 10.1016/j.jocn.2012.03.012. Epub 2012 Sep 15.

PMID:
22985932
13.

Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.

Miletic H, Niclou SP, Johansson M, Bjerkvig R.

Expert Opin Ther Targets. 2009 Apr;13(4):455-68. doi: 10.1517/14728220902806444 . Review.

PMID:
19335067
14.

Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development.

Hong YK, Chung DS, Joe YA, Yang YJ, Kim KM, Park YS, Yung WK, Kang JK.

Clin Cancer Res. 2000 Aug;6(8):3354-60.

15.

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.

Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G.

Mol Cancer Ther. 2009 Jul;8(7):1867-77. doi: 10.1158/1535-7163.MCT-09-0274. Epub 2009 Jul 7.

16.

Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells.

Read TA, Farhadi M, Bjerkvig R, Olsen BR, Rokstad AM, Huszthy PC, Vajkoczy P.

Cancer Res. 2001 Sep 15;61(18):6830-7.

17.

Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway.

Oliveira-Ferrer L, Wellbrock J, Bartsch U, Penas EM, Hauschild J, Klokow M, Bokemeyer C, Fiedler W, Schuch G.

Mol Cancer. 2013 Nov 20;12(1):144. doi: 10.1186/1476-4598-12-144.

18.

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.

Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM.

Clin Cancer Res. 2007 Jul 1;13(13):3942-50.

19.

Invasion as limitation to anti-angiogenic glioma therapy.

Lamszus K, Kunkel P, Westphal M.

Acta Neurochir Suppl. 2003;88:169-77. Review.

PMID:
14531575
20.

Neutrophils promote the malignant glioma phenotype through S100A4.

Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, de Groot JF.

Clin Cancer Res. 2014 Jan 1;20(1):187-98. doi: 10.1158/1078-0432.CCR-13-1279. Epub 2013 Nov 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk